Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter.

@article{Reiffel1998ImpactOS,
  title={Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter.},
  author={James A. Reiffel},
  journal={American heart journal},
  year={1998},
  volume={135 4},
  pages={551-6}
}
Antiarrhythmic agents may be beneficial or harmful. Among the harmful effects, or risks, is proarrhythmia. One of several factors that underlie proarrhythmic risk is the presence and nature of any underlying structural heart disease at the time of antiarrhythmic drug administration. The structural disease-antiarrhythmic drug interaction has been best studied and clearly delineated for class I antiarrhythmics. This review provides information to suggest that structural disease can enhance… CONTINUE READING